ALLO - Allogene Therapeutics Inc. (ALLO) Q1 2024 Earnings Call Transcript

2024-05-13 19:31:09 ET

Allogene Therapeutics, Inc. (ALLO)

Q1 2024 Earnings Conference Call

May 13, 2024, 05:00 PM ET

Company Participants

Christine Cassiano - Chief Corporate Affairs & Brand Strategy Officer

David Chang - President & Chief Executive Officer

Geoff Parker - Chief Financial Officer

Zachary Roberts - EVP, Research & Development and Chief Medical Officer

Conference Call Participants

Michael Yee - Jefferies

Tyler Van Buren - TD Cowen

Salveen Richter - Goldman Sachs

Reni Benjamin - Citizens JMP

Luca Issi - RBC Capital

Asthika Goonewardene - Truist

Brian Chinn - JPMorgan

Sami Corwin - William Blair

Jack Allen - Baird

John Newman - Canaccord

Kalpit Patel - B. Riley

Samantha Semenkow - Citi

Kelsey Goodwin - Guggenheim

Laura Prendergast - Raymond James

Carolina Ibanez Ventoso - Stifel

Presentation

Operator

Hello, and welcome to the Allogene Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be aware that today's conference is being recorded. We ask that you limit yourself to one question only.

I would now like to turn the conference over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. You may begin.

Christine Cassiano

Thank you, operator, and welcome to all who have joined this call.

After the market close today, Allogene issued a press release that provides a business update and financial results for the first quarter of 2024. This press release and today's webcast are both available on our website.

Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get to as many questions as possible.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research & Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer....

For further details see: